Brief: Theratechnologies Receives Refusal To File Letter For Trogarzo Intramuscular Method Of Administration sBLA From FDA
27/02/2024 12:42
Feb 27 (Reuters) - Theratechnologies Inc TH.TO :
* THERATECHNOLOGIES RECEIVES REFUSAL TO FILE LETTER FOR
TROGARZO®
INTRAMUSCULAR METHOD OF ADMINISTRATION SBLA FROM FDA
* THERATECHNOLOGIES INC: FDA DETERMINED THAT SBLA WAS NOT
SUFFICIENTLY COMPLETE TO PERMIT A SUBSTANTIVE REVIEW
* THERATECHNOLOGIES: WILL NOW ASSESS OPTIONS REGARDING
APPLICATION
Source text for Eikon: ID:nGNX1SRL6H
Further company coverage: TH.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theratechnologies
See all newsBrief: Theratechnologies Receives Final Court Approval On To Be Acquired By Future Pak
Brief: Theratechnologies Inc - Iss And Glass Lewis Recommend Voting 'For' Future Pak Arrangement
Canadian drugmaker Theratechnologies beats Q2 revenue estimates on strong demand
Brief: Theratechnologies Enters Into Definitive Agreement To Be Acquired By Cb Biotechnology, An Affiliate Of Future Pak
Brief: Theratechnologies Inc Decided To Further Evaluate Potential Sale Of Company Through An Open And Non-Exclusive Process